Skip To The Main Content

U.S. FDA Continues Data Integrity Focus

A Review of U.S. Regulations on cGMP and Data Integrity

The U.S. FDA continues to inspect pharmaceutical facilities for compliance with cGMP regulations, and as a result of these inspections, has issued numerous warning letters citing several significant violations involving data integrity.

You need to Login to view the full article. Please Login. Not a Member? Join today!
SHARE THIS ARTICLE
Advertisement

PDA Members Save Substantially